• Category

  • Content Type

Advertisement

No Local Reports Of Rare Blood Clots Linked To AstraZeneca Vaccine

By: , April 9, 2021
No Local Reports Of Rare Blood Clots Linked To AstraZeneca Vaccine
Photo: Donald De La Haye
Chief Medical Officer (CMO), Dr. Jacquiline Bisasor-McKenzie addressing the Ministry of Health and Wellness’ virtual COVID Conversations press briefing on April 8.

The Full Story

Chief Medical Officer (CMO), Dr. Jacquiline Bisasor-McKenzie, says, to date, there have been no local reports of blood clots with low platelets possibly associated with the administration of the AstraZeneca coronavirus (COVID-19) vaccine.

“As of April 7, over 47,000 persons have been vaccinated with the AstraZeneca vaccine, of which there have been no reports of this very rare event,” she said while addressing the Ministry of Health and Wellness’ weekly virtual COVID Conversations press briefing on April 8.

The CMO said that the World Health Organization (WHO) Advisory Committee and the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medical Agency (EMA) have been assessing, over time, the available safety data on the AstraZeneca vaccine and have concluded that the vaccine is not necessarily associated with an increase in the overall risk of blood clots, which are thromboembolic pulmonary and deep vein thrombosis (DVT) events.

She said the WHO has emphasised that although it is plausible that these events could be linked to the vaccine, this has not been confirmed and additional specialised studies are needed in order to better characterise the potential association between vaccination and risk factors.

Citing WHO/Pan American Health Organization (PAHO) data, Dr. Bisasor-McKenzie pointed out that approximately 200 million individuals have received the AstraZeneca COVID-19 vaccine globally, with 146 reports of the very rare events of blood clots with low platelets.

“Based on the available information, the WHO and EMA currently consider that the benefits of the AstraZeneca vaccine far outweighs the risk, given the risk of morbidity and mortality from COVID-19, and recommend that vaccinations continue,” she said.

Furthermore, she noted, the PAHO/WHO recommends that the safety of all COVID-19 vaccines should be monitored and encourages the reporting and investigation of the presumed adverse events.

Dr. Bisasor-McKenzie said that patients are advised to “seek immediate medical care if, especially within four to 20 days of vaccination, they have any difficulty breathing, chest pains, inflammation in the legs, persistent abdominal pain, neurological symptoms or small spots of blood under the skin beyond the injection site”.

“These are events that you can have with or without COVID vaccination, but if you have any of these events, you should report immediately to your doctor, and that’s our recommendation from the Ministry of Health and Wellness as well,” she said.

Last Updated: April 9, 2021

Skip to content